Research on a roll: FDA ad police tackle cancer drugs on TV

FDA Building 2
The FDA this week proposed another drug promotion research project to look at how consumers perceive cancer drug ads on TV. (FDA)

Oncology drugs on TV are the latest target on the FDA research radar. Wednesday, the agency’s Office of Prescription Drug Promotion (OPDP) unveiled plans for two tests to study the impact and effect of endpoint disclosures and superimposed text information with consumers.

Comments on the proposed DTC cancer research can be submitted through the end of February. The FDA previously posted a study of oncologists and the effect of cancer drug disclosures in advertising. That study, which closed to comments in late 2018, is listed as “research in progress” on the OPDP website.

RELATED: FDA promo police publicly smack Alkermes for omitting risk info from Vivitrol ad

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

The agency addressed the importance of cancer marketing as a research topic in response to comments then. When asked why the FDA had chosen to study oncology therapeutics and the doctors who prescribe them, the response noted the “dramatic rise in the number of oncology drugs brought to market” and the need to clarify endpoints used for FDA approval as well as those pharma companies use for their own assessments.

“In many cases, these endpoints are strictly exploratory and support only the reporting of descriptive results," the agency noted. "For clinicians who are not specifically trained in clinical trial design, interpreting these endpoints can be challenging. Pharmaceutical companies invest heavily in the development and distribution of promotional materials to educate oncologists about favorable clinical trial results.”

The proposed study is the third DTC research project announced by the FDA in less than two weeks. One of the other studies will investigate the impact of drug names in marketing, while the second—filed earlier this week—looks at the impact of endorsements from celebrities and online influencers.

RELATED: 2 November warning letters put FDA ad police on cusp of double-digit reprimands for 2019

But the new flurry of research proposals breaks an almost year-long lull. The last OPDP research project was proposed in March 2019, and it was the only one listed for the year on the OPDP research page. There are currently 12 total research-in-progress studies on the OPDP website, not including the three proposed this month.

Another five research projects, meanwhile, are listed as “research pending peer review and publication.” Some of those pending publication projects go back to 2013. It's possible that the results from some studies might not ever be publicly published, an FDA spokesperson said.

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.